ImmunityBio (IBRX) Capital Expenditures Growth (1y) (2015 - 2025)
ImmunityBio (IBRX) Capital Expenditures Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ImmunityBio | 7.60 Bn | 7.22 Bn | 43.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121.59% |
| Sep 30, 2025 | -191.98% |
| Jun 30, 2025 | 26.99% |
| Dec 31, 2024 | 71.03% |
| Sep 30, 2024 | 129.44% |
| Jun 30, 2024 | 183.41% |
| Mar 31, 2024 | -93.37% |
| Dec 31, 2023 | -166.91% |
| Sep 30, 2023 | -137.98% |
| Jun 30, 2023 | -104.79% |
| Mar 31, 2023 | 18,944.55% |
| Dec 31, 2022 | 2,283.51% |
| Sep 30, 2022 | 2,370.54% |
| Jun 30, 2022 | 63,919.12% |
| Mar 31, 2022 | -102.37% |
| Dec 31, 2021 | 48.52% |
| Jun 30, 2021 | -103.40% |
| Mar 31, 2021 | 1,062.67% |
| Dec 31, 2020 | -432.15% |
| Jun 30, 2020 | 52.05% |